Recent Updates
Recently added Catalysts
VNDA

Vanda Pharmaceuticals to Participate in the Citi 2015 Global Healthcare 1x1 Conference

Wednesday, November 4, 2015 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: WASHINGTON, Nov. 4, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that Mihael H. Polymeropoulo

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+121%
120-day peak, hindsight
Typical move
19.9%
average across 7 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
Imsidolimab
Phase 2 · Palmoplantar Pustulosis

Full Press Release Details

WASHINGTON, Nov. 4, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that Mihael H. Polymeropoulos, M.D., Vanda's President and CEO will participate in the Citi 2015 Global Healthcare 1x1 Conference on Thursday November 5, 2015, in New York City.
For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.
Senior Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
ShareAdd on Google
Tags: VNDA Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Nov 4, 2015

Biotech snapshot

Cash runway
$170M liquidity · $10M/mo burn
~16 mo
Low dilution risk
Lead asset
ImsidolimabPhase 2
Palmoplantar Pustulosis →

Catalyst track record

+121%
best trade around VNDA's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for VNDA.

See every catalyst's timing & PoA →